Armored immune cells take on liver cancer in early trial

NCT ID NCT05155189

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to standard therapies. C-CAR031 uses a patient's own immune cells, modified to better target and attack cancer cells. The trial will enroll 72 participants to evaluate safety and whether the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: C-CAR031 (armored CAR-T cells targeting GPC3)
What this could lead to: If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 72 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

The first affiliated hospital of Zhengzhou University
RECRUITING

Zhengzhou, China
the First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.